PRECIGEN Business Summary

Precigen, Inc. (PGEN) is a commercial-stage biopharmaceutical company that has transitioned from a legacy licensing and collaboration model to a product-driven revenue structure following the 2025 FDA approval of PAPZIMEOS (zopapogene imadenovec-drba) for recurrent respiratory papillomatosis (RRP). The company generates revenue through direct product sales of its first-in-class gene therapies, technology access fees, and milestone-based royalties from its proprietary AdenoVerse and UltraCAR-T platforms. Its operations are divided into two primary segments: Biopharmaceuticals, which focuses on precision medicines for immuno-oncology and infectious diseases, and Exemplar, which provides specialized porcine disease models for medical research. Precigen currently maintains a first-mover advantage in the RRP market, positioning itself as a specialized leader against direct competitors like Inovio Pharmaceuticals (developing INO-3107), as well as broader cell therapy players such as ImmunityBio and Iovance Biotherapeutics. The leadership team is led by President and CEO Helen Sabzevari, PhD, a prominent immuno-oncology expert who previously served as Senior Vice President of Immuno-Oncology at Merck KGaA/EMD Serono. The company was founded by Thomas David Reed, PhD, a molecular geneticist who remains a key scientific figure and board member. Other critical executives include Chief Financial Officer Harry Thomasian Jr., Chief Operating Officer Rutul R. Shah, and SVP of Research Douglas E. Brough, PhD, who oversees the technical advancement of the AdenoVerse platform. The board is chaired by Randal J. Kirk, a veteran biotech investor and former CEO of Intrexon (Precigen’s predecessor), with significant institutional backing from firms such as Patient Capital Management and strategic credit financing from Pharmakon Advisors.